Table 4 Average anticholinergic burden in CFAS I and CFAS II, by age, sex, cognition and disability
Population | Mean ACB sum (95% CI) | Adjusted rate ratio for CFAS II vs CFAS Ia | ||
|---|---|---|---|---|
CFAS I | CFAS II | Rate ratio (95% CI) | pb | |
Overall | 0.99 (0.96, 1.03) | 1.11 (1.08, 1.15) | 1.12 (1.07, 1.17) | < 0.001 |
By sex | ||||
Male | 0.91 (0.86, 0.95) | 0.96 (0.92–1.01) | 1.00 | 0.01 |
Female | 1.05 (1.01, 1.09) | 1.23 (1.18–1.28) | 1.12 (1.03, 1.23) | |
By age, years | ||||
64–69 | 0.87 (0.81, 0.92) | 0.81 (0.75–0.87) | 1.00 | < 0.001 |
70–74 | 0.97 (0.91, 1.04) | 1.10 (1.03–1.66) | 1.21 (1.05, 1.38) | |
75–79 | 1.09 (1.02, 1.15) | 1.26 (1.18–1.34) | 1.24 (1.09, 1.42) | |
80–84 | 1.12 (1.04, 1.20) | 1.28 (1.19–1.36) | 1.22 (1.06, 1.41) | |
85–89 | 1.07 (0.95, 1.18) | 1.37 (1.25–1.49) | 1.39 (1.17, 1.66) | |
90+ | 0.97 (0.77, 1.17) | 1.36 (1.17–1.54) | 1.53 (1.17, 1.99) | |
By cognition | ||||
MMSE ≤21 | 1.29 (1.13, 1.46) | 1.32 (1.13, 1.52) | 1.00 | 0.03 |
MMSE 22–25 | 1.09 (1.02, 1.16) | 1.38 (1.28, 1.48) | 1.11 (0.94, 1.31) | |
MMSE 26–30 | 0.93 (0.89, 0.97) | 1.04 (1.01, 1.09) | 0.97 (0.83, 1.13) | |
By disability | ||||
No impairment | 0.76 (0.72, 0.79) | 0.85 (0.81, 0.89) | 1.00 | 0.91 |
IADL impairment | 1.51 (1.40, 1.61) | 1.64 (1.54, 1.74) | 1.02 (0.92, 1.13) | |
ADL impairment | 1.85 (1.71, 1.99) | 1.88 (1.74, 2.03) | 1.02 (0.91, 1.14) | |